Inmune Bio, Inc. (INMB) — 8-K Filings

8-K Filings (50)

• Inmune Bio Files 8-K: Material Agreement & Exhibits — Dec 23, 2025 Risk: medium
  On December 22, 2025, Inmune Bio, Inc. filed an 8-K report. The filing indicates an entry into a material definitive agreement and includes financial statements
• Inmune Bio Files 8-K: Material Agreement & Exhibits — Dec 19, 2025 Risk: medium
  On December 19, 2025, Inmune Bio, Inc. filed an 8-K report. The filing indicates an entry into a material definitive agreement and includes financial statements
• Inmune Bio, Inc. Terminates Material Agreement — Dec 10, 2025 Risk: medium
  On December 5, 2025, Inmune Bio, Inc. reported the termination of a material definitive agreement. The filing does not specify the counterparty or the nature of
• 8-K Filing — Dec 8, 2025
• 8-K Filing — Dec 5, 2025
• 8-K Filing — Dec 3, 2025
• Inmune Bio, Inc. Files 8-K: Director & Officer Changes — Nov 28, 2025 Risk: medium
  On November 26, 2025, Inmune Bio, Inc. filed an 8-K report detailing changes in its board of directors and executive officers, as well as updates to compensator
• 8-K Filing — Nov 18, 2025
• 8-K Filing — Nov 10, 2025
• Inmune Bio, Inc. Files 8-K Report — Oct 28, 2025 Risk: low
  On October 23, 2025, Inmune Bio, Inc. filed an 8-K report. The filing indicates that the company is a biotechnology firm incorporated in Nevada, with its princi
• Inmune Bio, Inc. Files 8-K Report — Sep 30, 2025 Risk: low
  On September 29, 2025, Inmune Bio, Inc. filed an 8-K report. The filing indicates the company's principal executive offices are located at 225 NE Mizner Blvd, S
• Inmune Bio Files 8-K Report — Jul 29, 2025 Risk: low
  On July 29, 2025, Inmune Bio, Inc. filed an 8-K report. The filing primarily concerns "Other Events" and "Financial Statements and Exhibits," indicating updates
• Inmune Bio Files 8-K Report — Jul 25, 2025 Risk: low
  On July 24, 2025, Inmune Bio, Inc. filed an 8-K report. The filing primarily concerns "Other Events" and "Financial Statements and Exhibits," with no specific m
• 8-K Filing — Jun 30, 2025
• Inmune Bio Files 8-K Report — Jun 26, 2025 Risk: low
  On June 26, 2025, Inmune Bio, Inc. filed an 8-K report. The filing indicates "Other Events" and "Financial Statements and Exhibits" as key items. No specific fi
• Inmune Bio Files 8-K: Director Changes, Officer Appointments, Shareholder Votes — Jun 10, 2025 Risk: medium
  On June 10, 2025, Inmune Bio, Inc. filed an 8-K report detailing several key events. These include the departure of directors or certain officers, the election
• Inmune Bio Files 8-K Report — May 14, 2025 Risk: low
  On May 14, 2025, Inmune Bio, Inc. filed an 8-K report. The filing primarily concerns "Other Events" and "Financial Statements and Exhibits," indicating updates
• Inmune Bio Files 8-K on Financials — May 8, 2025 Risk: low
  On May 8, 2025, Inmune Bio, Inc. filed an 8-K report. The filing primarily concerns the company's financial condition and results of operations, with no specifi
• Inmune Bio, Inc. Files 8-K: Accountant Change & Exhibits — May 7, 2025 Risk: low
  On May 7, 2025, Inmune Bio, Inc. filed an 8-K report. The filing primarily concerns changes in the registrant's certifying accountant and includes financial sta
• Inmune Bio Files 8-K Report — May 5, 2025 Risk: low
  On May 5, 2025, Inmune Bio, Inc. filed an 8-K report. The filing primarily concerns "Other Events" and "Financial Statements and Exhibits," indicating updates o
• Inmune Bio Files 8-K for Disclosure and Exhibits — Apr 16, 2025 Risk: low
  On April 16, 2025, Inmune Bio, Inc. filed an 8-K report. The filing primarily concerns Regulation FD Disclosure and the submission of Financial Statements and E
• Inmune Bio Files 8-K Report — Apr 14, 2025 Risk: low
  On April 14, 2025, Inmune Bio, Inc. filed an 8-K report. The filing primarily concerns "Other Events" and "Financial Statements and Exhibits," indicating update
• Inmune Bio Files 8-K: Regulation FD & Exhibits — Apr 9, 2025 Risk: low
  On April 3, 2025, Inmune Bio, Inc. filed an 8-K report. The filing primarily concerns a Regulation FD Disclosure and the filing of Financial Statements and Exhi
• Inmune Bio Files 8-K Report — Apr 1, 2025 Risk: low
  On April 1, 2025, Inmune Bio, Inc. filed an 8-K report. The filing primarily concerns "Other Events" and "Financial Statements and Exhibits," with no specific m
• Inmune Bio Files 8-K: Financials & Exhibits — Mar 24, 2025 Risk: low
  On March 24, 2025, Inmune Bio, Inc. filed an 8-K report. The filing primarily concerns financial statements and exhibits, with no specific material events or ot
• 8-K Filing — Mar 4, 2025
• Inmune Bio Files 8-K Report — Feb 12, 2025 Risk: low
  On February 12, 2025, Inmune Bio, Inc. filed an 8-K report. The filing primarily concerns "Other Events" and "Financial Statements and Exhibits," indicating upd
• 8-K Filing — Feb 10, 2025
• Inmune Bio Files 8-K Report — Jan 28, 2025 Risk: low
  On January 28, 2025, Inmune Bio, Inc. filed an 8-K report. The filing primarily concerns "Other Events" and "Financial Statements and Exhibits," indicating upda
• Inmune Bio Files 8-K: Material Agreements & Board Changes — Dec 9, 2024 Risk: medium
  On December 4, 2024, Inmune Bio, Inc. entered into a material definitive agreement related to its business operations. The company also reported on modification
• Inmune Bio Files 8-K Report — Nov 14, 2024 Risk: medium
  On November 13, 2024, Inmune Bio, Inc. filed an 8-K report. The filing primarily concerns "Other Events" and "Financial Statements and Exhibits," indicating upd
• Inmune Bio Files 8-K Report — Nov 13, 2024 Risk: low
  On November 13, 2024, Inmune Bio, Inc. filed an 8-K report. The filing primarily concerns Regulation FD Disclosure and Financial Statements and Exhibits. No spe
• Inmune Bio Files 8-K on Financials — Nov 1, 2024 Risk: low
  Inmune Bio, Inc. filed an 8-K on November 1, 2024, reporting on its results of operations and financial condition as of October 31, 2024. The filing details the
• Inmune Bio Files 8-K with Financial Statements — Oct 28, 2024 Risk: low
  On October 28, 2024, Inmune Bio, Inc. filed an 8-K report. The filing primarily concerns financial statements and exhibits, indicating a routine update rather t
• Inmune Bio Appoints Dr. David M. Reifman as CMO — Oct 25, 2024 Risk: medium
  On October 24, 2024, Inmune Bio, Inc. filed an 8-K report detailing the appointment of Dr. David M. Reifman as Chief Medical Officer. Dr. Reifman brings extensi
• Inmune Bio Files 8-K Report — Oct 24, 2024 Risk: medium
  On October 24, 2024, Inmune Bio, Inc. filed an 8-K report. The filing primarily concerns "Other Events" and "Financial Statements and Exhibits," indicating upda
• Inmune Bio Files 8-K: Other Events & Financials — Oct 11, 2024 Risk: medium
  On October 11, 2024, Inmune Bio, Inc. filed an 8-K report. The filing primarily concerns "Other Events" and "Financial Statements and Exhibits," indicating upda
• Inmune Bio Files 8-K: Financial Statements & Exhibits — Sep 26, 2024 Risk: low
  On September 26, 2024, Inmune Bio, Inc. filed an 8-K report. The filing primarily concerns financial statements and exhibits, indicating a routine update rather
• Inmune Bio Files 8-K for Financials and Exhibits — Sep 17, 2024 Risk: low
  On September 17, 2024, Inmune Bio, Inc. filed an 8-K report. The filing primarily concerns financial statements and exhibits, indicating a routine update rather
• Inmune Bio, Inc. Files 8-K for Material Agreement — Sep 16, 2024 Risk: medium
  On September 12, 2024, Inmune Bio, Inc. entered into a material definitive agreement. The company also reported other events and filed financial statements and
• Inmune Bio Inc. CMO & President Resigns — Sep 3, 2024 Risk: medium
  On September 3, 2024, Inmune Bio, Inc. filed an 8-K report detailing the resignation of Dr. David M. Siegel from his positions as Chief Medical Officer and Pres
• Inmune Bio, Inc. Files Material Definitive Agreement 8-K — Aug 9, 2024 Risk: medium
  On August 9, 2024, Inmune Bio, Inc. filed an 8-K report detailing a material definitive agreement. The filing does not provide specific details on the agreement
• Inmune Bio, Inc. Files 8-K Report — Aug 2, 2024 Risk: low
  On August 1, 2024, Inmune Bio, Inc. filed an 8-K report detailing its financial results and operations. The company, incorporated in Nevada, is focused on biolo
• Inmune Bio Files 8-K Report — Jul 30, 2024 Risk: low
  On July 25, 2024, Inmune Bio, Inc. filed an 8-K report. The filing primarily concerns "Other Events" and "Financial Statements and Exhibits," with no specific n
• Inmune Bio Files 8-K on Security Holder Votes — Jul 19, 2024 Risk: low
  Inmune Bio, Inc. filed an 8-K on July 19, 2024, to report on matters submitted to a vote of its security holders. The filing does not contain specific details a
• Inmune Bio Announces Board and Executive Compensation Changes — Jul 5, 2024 Risk: medium
  On July 5, 2024, Inmune Bio, Inc. filed an 8-K report detailing changes in its board of directors and executive compensation. The filing indicates the election
• Inmune Bio Terminates Acepodia Deal Over Missed Milestones — Jul 1, 2024 Risk: medium
  On June 27, 2024, Inmune Bio, Inc. filed an 8-K report detailing the termination of its collaboration and license agreement with Acepodia, Inc. The termination
• Inmune Bio Appoints New CMO, Restructures Executive Roles — Jun 13, 2024 Risk: medium
  On June 10, 2024, Inmune Bio, Inc. filed an 8-K report detailing changes in its board of directors and executive compensation. The company elected Dr. David M.
• Inmune Bio Director Resigns — May 30, 2024 Risk: medium
  On May 30, 2024, Inmune Bio, Inc. filed an 8-K report detailing the resignation of David L. Sidransky from its Board of Directors. The filing also includes fina
• Inmune Bio Files 8-K for Corporate Amendments — May 23, 2024 Risk: low
  On May 22, 2024, Inmune Bio, Inc. filed an 8-K report detailing amendments to its Articles of Incorporation and the filing of financial statements and exhibits.

Popular Companies

AAPL · TSLA · MSFT · AMZN · GOOGL · META · NVDA · JPM · BRK-B · V · JNJ · UNH · XOM · WMT · MA · PG · HD · DIS · BAC · NFLX